While in normal cells, this would lead to cell cycle arrest (61), activating mutations in BRAF and NRAS, combined with mutation in tumor suppressors such as PTEN and can result in robust mitogenic signaling and translation of CCND1, which may “override” CDKN1A/p21-mediated checkpoint activation. The gene discussed is PTEN; the disease is neoplasm.